www.ema.europa.eu PRAC agrees new safety information on desogestrel- and etonogestrel-containing contraceptives and Litfulo, a medicine to treat alopecia areata    Desogestrel- and etonogestrel-containing medicines: risk of meningioma and new measures to minimise this risk  PRAC agreed on a...

www.ema.europa.eu EMA’s human medicines committee (CHMP) has started a phased review of data on daraxonrasib, a medicine intended for the treatment of metastatic pancreatic cancer. A phased review aims to accelerate the assessment of a medicine by evaluating the data in phases, as they...

www.ema.europa.eu EMA’s initiatives in this area will be discussed through a dedicated women’s health workshop on 28-29 September. The workshop, broadcast live, will take stock of current activities across the EU, including from EMA, national regulators and other organisations. It will...

www.ema.europa.eu Six new medicines recommended for approval EMA’s human medicines committee (CHMP) recommended six medicines for approval at its June 2026 meeting. The committee recommended granting a marketing authorisation for Aujemflu (influenza virus surface antigens (haemagglutinin...